M.D. Anderson Cancer Center: Carcinoma, Squamous Cell trials

The registry lists 33 Carcinoma, Squamous Cell studies with M.D. Anderson Cancer Center as lead sponsor. 2 are open to participants now and 12 have results posted.

Early Phase 1 2Phase 1 9Phase 2 19Phase 3 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant LesionsNot yet recruitingNCT07631013Phase 1
• Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)RecruitingNCT05027633Phase 2
• Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell CancerCompletedNCT04555837Phase 1/2Results posted
• Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell CancerTerminatedNCT04220775Phase 1/2Results posted
• Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility TrialCompletedNCT03690921Phase 2Results posted
• Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare TumorsCompletedNCT03108131Phase 2Results posted
• Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell CarcinomaCompletedNCT01198028Phase 2Results posted
• Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and NeckCompletedNCT01064479Phase 2Results posted
• Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the SkinTerminatedNCT01059305Phase 2Results posted
• Preoperative Treatment With Cetuximab and/or IMC-A12CompletedNCT00957853Phase 2Results posted
• Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell CarcinomaCompletedNCT00942734Phase 2Results posted
• Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the PenisCompletedNCT00512096Phase 2Results posted
• Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell CancerCompletedNCT00485485Phase 2Results posted
• ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the SkinCompletedNCT00054691Phase 2Results posted
• Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCCWithdrawnNCT06762808Phase 2
• Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).Active, not recruitingNCT05681039Phase 2
• Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell CarcinomaWithdrawnNCT05535023Phase 2
• A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell CarcinomaTerminatedNCT05322135Early Phase 1
• 4-Point Therapy Response Score With PET/CT for Anal Squamous Cell CancerCompletedNCT05130073
• Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck CancerCompletedNCT04870840Phase 1
• Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell CancerWithdrawnNCT04834349Phase 2
• Nutritional Supplementation in Reducing Complications in Patients With Locally Advanced Esophageal Cancer Undergoing Chemotherapy, Radiation Therapy, and/or SurgeryWithdrawnNCT04029857Phase 3
• Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal DiseaseCompletedNCT03868020Early Phase 1
• Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar CancersCompletedNCT03452332Phase 1
• Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell CancerCompletedNCT03144778Phase 1
• Intensity-Modulated Proton Therapy (IMPT) or TransOral Robotic Surgery (TORS) for the Treatment of Low-Risk Oropharynx Squamous CellStatus unknownNCT02663583
• Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) TrialActive, not recruitingNCT01512589Phase 2
• Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)WithdrawnNCT01427205Phase 2
• Sexual Behavior in Head and Neck Cancer PatientsStatus unknownNCT00662662
• Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell CancerCompletedNCT00507858Phase 1
• Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)CompletedNCT00113347Phase 1
• A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell CancerCompletedNCT00038584Phase 1
• Assessment of Head and Neck Tumor Hypoxia Using 18F-FluoromisonidazoleWithdrawnNCT00038038Not applicable